STOCKHOLM, SWEDEN – May 5, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has been awarded a research grant by The Michael J. Fox Foundation (MJFF) amounting to USD 420,000. The grant will finance preclinical studies to evaluate the potential treatment effect of golexanolone in Parkinson’s disease.
Karolinska Development’s portfolio company Umecrine Cognition receives grant from The Michael J. Fox Foundation
Seeking Alpha / 1 hour ago 1 Views
Comments